Posts Tagged ‘Erlotinib hydrochloride’

Erlotinib Hydrochloride is a baby atom inhibitor of the EGFR/HER-1 (human epidermal advance agency receptor) tyrosine kinase. Overexpression of the EGFR is present in abounding carcinomas, and inhibition of the activating kinase by Erlotinib provides a actinic action aloft these systems. The inhibition of this tyrosine kinase finer blocks EGFR action but does not abolish bump growth. When accumulated with 3,3′-diindolylmethane (sc-204624), ability adjoin bump admeasurement was demonstrated.

Selective inhibition of EGFR tyrosine kinase by erlotinib hydrochloride leads to the disruption of blight advance and development which cover corpuscle migration, proliferation, angiogenesis, and apoptosis. For instance, erlotinib hydrochloride was apparent to abet corpuscle apoptosis and G0/G1 corpuscle aeon arrest in hepatocellular blight cells, Bxpc-3 and PANC-1 cells, thereby acceptable chemosensitivity appear cytostatics.

In addition, this artefact is broadly researched and acclimated for the analysis of animal avant-garde non-small corpuscle lung blight (NSCLC). In pancreatic cancer, erlotinib hydrochloride was aswell appear to display an anti-tumour effect.

CAS:183319-69-9

Molecular formula:C22H23N3O4.HCl

Molecular weight:429.9

Appearance: Off-white to pale yellow powder

Solubility: Soluble in DMSO at 18 mg/mL with warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.

Storage: Store at -20° C

Application: An HER-1/EGFR tyrosine kinase inhibitor

Usage:

drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor

Product description:Erlotinib hydrochloride is an HER-1/EGFR tyrosine kinase inhibitora, a small molecule inhibitor of the human epidermal growth factor receptor (HER-1/EGFR) tyrosine kinase. Overexpression of the EGFR is present in many carcinomas, and inhibition of the activating kinase by Erlotinib provides a chemical intervention upon these systems.